Atlas Trials

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT03701321 · WITHDRAWN

Trial details

NCT number
NCT03701321
Sponsor
National Cancer Institute (NCI)
Status
WITHDRAWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Start date
2019-01-25
Primary completion
2020-05-28
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.